Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758830 | 0.96 | HRH4 (0.69) | HRH4HRH3LMNATSHRNR4A1 | |
| SCHEMBL17628082 | 0.86 | HRH4 (0.51) | HRH4HRH3LMNATSHRNR4A1 | |
| SCHEMBL1616617 | 0.83 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL3237060 | 0.82 | HRH4 (0.51) | HRH4HRH3AKT1OPRM1OPRK1 | |
| SCHEMBL602624 | 0.80 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL602625 | 0.80 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL17628018 | 0.80 | HRH4 (0.45) | HRH4LMNATSHRNR4A1SMN1; SMN2 | |
| SCHEMBL3235125 | 0.80 | HRH4 (0.68) | HRH4HRH3AKT1OPRM1OPRK1 | |
| SCHEMBL3237073 | 0.80 | HRH4 (0.60) | HRH4HRH3LMNATSHRAKT1 | |
| SCHEMBL3236710 | 0.80 | HRH4 (0.48) | HRH4HRH3AKT1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB PHARMA, S.A. (BE) | 2010-11-25 | — | — | US | claimed |
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB PHARMA, S.A. (BE) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | HRH4, HRH2, HRH3 | HRH4 1/4885HRH3 3/4885LMNA 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.